Linked-in Link Twitter Link

Dr Andrew McNair Appointed as Innova Partnerships Managing Director

Jul 21, 2017

Innova Partnerships is pleased to announce the appointment of Dr Andrew McNair as Managing Director of the business, effective immediately.

Innova Partnerships was set up in 2006 to support and build value in life science companies. Since then, Innova Partnerships has gone on to build a portfolio of companies that benefit from an innovative approach to commercialisation and growth. These include companies like the Kings College London spin-out dental business, Reminova Ltd and the Edinburgh-based digital health company, RelayMed.

In June 2017, one of Innova Partnerships portfolio businesses was sold to German diagnostics company Sygnis AG.  This was the second successful portfolio exit in the recent period and confirms our goal to add value to the companies we work with.

Innova also advises high growth life sciences businesses across the UK and is working with several UK universities to provide commercialisation and spin-out support.

Andy initially joined the Board of Innova Partnerships as a Non-executive Director in 2007, taking up a full time role as interim Chief Operating Officer in January 2017. His appointment as Managing Director strengthens the team and positions the business for further growth. Professor Steve Howell, Innova’s Founder, will now focus on working with our portfolio businesses.

Steve Howell commented;

“I am delighted that Andy has accepted this new role. He has guided the business as a non-exec on our Board and is now in a position to drive the business forward and build on our successful 10 year history working with companies and organisations across the life sciences sector. The whole Innova team and I look forward to working with him in his new role.”

Dr. Andrew McNair, added;

“Having worked with Steve and the team since the early days of the company, I am thrilled to accept the position of Managing Director.  The company has an excellent multi-disciplinary team committed to building a strong and sustainable portfolio of life sciences businesses and I very much look forward to contributing to our success over the next 10 years.”